close

Enter

Log in using OpenID

Insulin Biosimilars Market

embed
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin.
Insulin Biosimilars
2018-2026
Market
Trends
And
Outlook
Diabetes is a group of metabolic disease characterized by high blood sugar level due to
inadequate secretion of insulin. Common symptoms of diabetes include increased hunger,
tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is
increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World
Health Organization (WHO) report in 2014, globally around 422 million adults were living with
diabetes and 1.5 million people died due to the disease in 2012. Insulin biosimilar has the
ability to increase access to treatment of diabetes mellitus among the patients while reducing
treatment costs.
Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1750
Biosimilar is a medicine developed on the original biological reference product. The production
process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar
product is unique from the other. Biosimilar manufactures use different culture conditions,
master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising
prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For
instance, According to 2013 American Society For Metabolic And Bariatric Surgery report,
obesity was a major independent risk factor for developing the disease, and more than 90% of
type 2 diabetics population are overweight or obese due to growing adoption of unhealthy
lifestyle. Insulin is distributed and manufactured by small number of multinational companies in
emerging economies, beyond the established biosimilar manufactures, and a handful of small
players are developing insulin manufacturing capacities based on modern biotechnological
methods in turn, boosting growth of the insulin biosimilars market size.
Report includes chapters which deeply display the following deliverable about industry :
• Insulin Biosimilars Market Research Objective and Assumption
• Insulin Biosimilars Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Insulin Biosimilars Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Insulin Biosimilars Market, By Regions
• Insulin Biosimilars Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Insulin Biosimilars Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Insulin Biosimilars Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Insulin Biosimilars Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Insulin Biosimilars Market – Dynamics
Increasing number of manufacturers are developing biosimilar insulin to provide clinical aid that
are similar to current insulin analogs at the more affordable price. Moreover, the patents of
several insulin manufacturing companies are soon expected to lose patent protection, For
instance, LEVEMIR an Insulin detemir by Novo Nordisk is going to lose its patent rights in year
2019, which is influencing numerous pharmaceutical key manufacturers to develop alternatives
to patents, referred as biosimilar. The low cost of biosimilar insulin for diabetes treatment and
effectiveness is helping treat patients suffering from diabetes mellitus. Companies are also
focusing on developing medical devices that allows for less painful and safe delivery of the
biosimilar insulin treatment, which in turn, is boosting market growth. Government agencies are
focusing on the endorsement of insulin biosimilar by funding research and development.
Furthermore, rising geriatric population across the globe and increasing demand for rapid-acting
insulin analogues is boosting growth of the insulin biosimilar market. For instance, according to
a consensus report published in 2012 American Diabetes Association, showed over 25% of the
U.S. population aged ≥65 years suffered from diabetes.
However, critical regulatory requirements for approval of insulin biosimilar products besides
strong opposition from branded manufactures regarding patent rights, high cost of production,
manufacturing complexities, and various safety concerns associated with changes in drug
formulations pose as factors hampering growth of the insulin biosimilars market.
Insulin Biosimilars Market – Regional Insights
On the basis of region, the global insulin biosimilars market is segmented into North America,
Europe, Latin America, Asia Pacific, Middle East, and Africa. North America leads the global
insulin biosimilar market, owing to rising geriatric population and high prevalence of diabetesrelated disorders in the region. Moreover, government support for diabetes-free states is
accelerating growth of the insulin biosimilar market in North America. For instance, Centers for
Disease Control and Prevention (CDC) runs a National Diabetes Prevention Program in various
U.S states.
The market in Europe accounts for the second-leading share in the global market, mainly due
to increasing number of primary approvals for biosimilar insulin. For example, European
Commission (EC) approved Mylan and Biocon’s biosimilar insulin—Glargine—for treating
diabetes on March 27, 2018. Asia Pacific market is expected to gain significant traction over the
forecast period due to increasing government support, improving healthcare conditions and
growing diabetes incidence in the region. For instance, 2011 World Health Organization report
shows that diabetes deaths will double between 20011 and 2030.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/insulin-biosimilars-market-1750
Insulin Biosimilars Market – Competitive Insights
The key players operating in the global insulin biosimilars market includes Boehringer
Ingelheim, Pfizer Inc., Biocon, Merck & Co., Mylan N.V., Eli Lilly & Co., Wockhardt Limited,
NOVO Nordisk A/S, Sanofi S.A., Ypsomed AG and others Key players are engaged in developing
new technologies and collaborations in order to retain dominant position in the market. For
instance on 2018 Sandoz, a Norartis division and Asia’s premier biopharmaceutical company,
Biocon announced exclusive global collaboration for next generation biosimilars.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Author
Alex Huge
Alex Huge369   documents Email
Document
Category
Health and Medicine
Views
3
File Size
123 KB
Tags
market, Insulin Biosimilars Market
1/--pages
Report inappropriate content